Estrone sulfate potassium
Estrone sulfate potassium structure
|
Common Name | Estrone sulfate potassium | ||
|---|---|---|---|---|
| CAS Number | 1240-04-6 | Molecular Weight | 389.52800 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H21KO5S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07, GHS08 |
Signal Word | Warning | |
Use of Estrone sulfate potassiumEstrone sulfate potassium is a natural endogenous steroid and is an estrogen ester and conjugate[1]. |
| Name | Estrone 3-sulfate potassium salt |
|---|---|
| Synonym | More Synonyms |
| Description | Estrone sulfate potassium is a natural endogenous steroid and is an estrogen ester and conjugate[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C18H21KO5S |
|---|---|
| Molecular Weight | 389.52800 |
| Exact Mass | 389.08300 |
| PSA | 89.05000 |
| LogP | 4.37420 |
| Appearance of Characters | off-white to light tan |
| Storage condition | −20°C |
| Symbol |
GHS07, GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H319-H335-H361 |
| Precautionary Statements | P261-P281-P305 + P351 + P338 |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
|
Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions.
J. Pharm. Sci. 102(1) , 280-8, (2013) We aimed to explore the major active components in grapefruit juice (GFJ), orange juice (OJ), and apple juice (AJ) that are responsible for OATP2B1-mediated drug interactions, by means of in vitro stu... |
|
|
Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.
Eur. J. Pharm. Sci. 47(1) , 244-55, (2012) To support drug development, the drug-drug interaction potential (DDI) of an investigational drug (AZX) was assessed against the probe estradiol 17β-glucuronide as well as against simvastatin acid, at... |
|
|
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Eur. J. Cancer 50(6) , 1055-64, (2014) Recent data have raised concern about the clinical efficacy of aromatase inhibitors in overweight and/or obese breast cancer patients. We report in vivo aromatase inhibition and plasma and tissue oest... |
| potassium,[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate |